SI0819122T1 - 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity - Google Patents

1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity

Info

Publication number
SI0819122T1
SI0819122T1 SI9630434T SI9630434T SI0819122T1 SI 0819122 T1 SI0819122 T1 SI 0819122T1 SI 9630434 T SI9630434 T SI 9630434T SI 9630434 T SI9630434 T SI 9630434T SI 0819122 T1 SI0819122 T1 SI 0819122T1
Authority
SI
Slovenia
Prior art keywords
pdeiv
phenylalkyl
imidazol
dihydro
derivatives
Prior art date
Application number
SI9630434T
Other languages
English (en)
Slovenian (sl)
Inventor
Eddy Jean Edgard Freyne
Gaston Stanislas Marcella Diels
Gil Jose Ignacio Andres
Gadea Francisco Javier Fernandez
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI0819122T1 publication Critical patent/SI0819122T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9630434T 1995-04-06 1996-03-28 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity SI0819122T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP95200868 1995-04-06
EP95202898 1995-10-26
PCT/EP1996/001394 WO1996031485A1 (en) 1995-04-06 1996-03-28 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity
EP96909150A EP0819122B1 (en) 1995-04-06 1996-03-28 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity

Publications (1)

Publication Number Publication Date
SI0819122T1 true SI0819122T1 (en) 2002-06-30

Family

ID=26139205

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630434T SI0819122T1 (en) 1995-04-06 1996-03-28 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity

Country Status (27)

Country Link
US (2) US5994376A (no)
EP (1) EP0819122B1 (no)
JP (1) JP4562101B2 (no)
KR (1) KR100406628B1 (no)
CN (1) CN1068591C (no)
AR (1) AR002732A1 (no)
AT (1) ATE214052T1 (no)
AU (1) AU702947B2 (no)
CA (1) CA2216653C (no)
CY (1) CY2328B1 (no)
CZ (1) CZ293127B6 (no)
DE (1) DE69619661T2 (no)
DK (1) DK0819122T3 (no)
ES (1) ES2174064T3 (no)
HK (1) HK1007880A1 (no)
HR (1) HRP960155A2 (no)
HU (1) HU223324B1 (no)
IL (1) IL117807A (no)
MX (1) MX9707652A (no)
MY (1) MY119254A (no)
NO (1) NO314339B1 (no)
NZ (1) NZ304877A (no)
PL (1) PL187375B1 (no)
PT (1) PT819122E (no)
SI (1) SI0819122T1 (no)
TW (1) TW332201B (no)
WO (1) WO1996031485A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
SK285878B6 (sk) * 1996-10-02 2007-10-04 Janssen Pharmaceutica N. V. Derivát 2-kyaniminoimidazolu, prostriedok obsahujúci tento derivát, spôsob prípravy tohto prostriedku, uvedený derivát na použitie ako liečivo, použitie tohto derivátu na prípravu liečiva a spôsob prípravy tohto derivátu
NZ501627A (en) 1997-07-10 2002-02-01 Janssen Pharmaceutica Nv 3,5-dioxo-2(3H)-triazine derivatives substituted by 4-(phenylmethyl)phenyl useful as IL-5 inhibitors
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
SK284468B6 (sk) * 1998-04-01 2005-04-01 Janssen Pharmaceutica N. V. Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy
CA2328250A1 (en) * 1998-04-14 1999-10-21 Cornelia Jutta Forster Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
US6172118B1 (en) * 1998-04-14 2001-01-09 Smithkline Beecham Corporation Compounds
ES2198980T3 (es) * 1998-11-23 2004-02-01 Janssen Pharmaceutica N.V. Derivados de 6-azauralico inhibidores de il-5.
ATE365723T1 (de) 1998-12-18 2007-07-15 Janssen Pharmaceutica Nv Il-5 hemmende 6-uracilderivate
AU2001290884B2 (en) * 2000-09-13 2005-12-15 Merck & Co., Inc. Alpha V integrin receptor antagonists
CA2447618A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
CN1997367B (zh) * 2004-07-05 2010-11-24 同和药品株式会社 预防和治疗过敏性炎症的组合物
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL285394A (no) * 1961-11-17
US3184060A (en) 1963-02-13 1965-05-18 Owens Illinois Glass Co Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
DE69332762T2 (de) * 1992-12-02 2003-08-14 Pfizer Inc., New York Cathecoldiether als selektive pde iv hemmungsmittel
TW263495B (no) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
PL322654A1 (en) 1998-02-16
NO314339B1 (no) 2003-03-10
EP0819122A1 (en) 1998-01-21
DK0819122T3 (da) 2002-07-01
PT819122E (pt) 2002-08-30
CN1181072A (zh) 1998-05-06
EP0819122B1 (en) 2002-03-06
AU702947B2 (en) 1999-03-11
NZ304877A (en) 1999-06-29
WO1996031485A1 (en) 1996-10-10
HUP9801575A3 (en) 1999-03-01
KR100406628B1 (ko) 2004-05-31
US5994376A (en) 1999-11-30
JP4562101B2 (ja) 2010-10-13
HUP9801575A2 (hu) 1999-01-28
DE69619661T2 (de) 2002-10-31
DE69619661D1 (de) 2002-04-11
PL187375B1 (pl) 2004-06-30
CN1068591C (zh) 2001-07-18
ES2174064T3 (es) 2002-11-01
KR19980703449A (ko) 1998-11-05
CA2216653A1 (en) 1996-10-10
AR002732A1 (es) 1998-04-29
HU223324B1 (hu) 2004-06-28
IL117807A0 (en) 1996-08-04
NO974602D0 (no) 1997-10-06
HK1007880A1 (en) 1999-04-30
HRP960155A2 (en) 1997-10-31
MX9707652A (es) 1997-11-29
TW332201B (en) 1998-05-21
CY2328B1 (en) 2004-02-06
JPH11503136A (ja) 1999-03-23
CA2216653C (en) 2009-05-26
NO974602L (no) 1997-10-06
CZ293127B6 (cs) 2004-02-18
CZ314997A3 (cs) 1998-12-16
US6403805B1 (en) 2002-06-11
US20020068830A1 (en) 2002-06-06
MY119254A (en) 2005-04-30
AU5275596A (en) 1996-10-23
IL117807A (en) 2001-06-14
ATE214052T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
HK1007880A1 (en) 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity
NZ329176A (en) 2,5-dioxo-imidazolidine derivatives and medicaments
EP0728749A3 (en) Triazine derivatives, their preparation and their application
GB2297443B (en) Amplifier
AU7908098A (en) Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
HUP9801817A3 (en) Dolastatin derivatives, their preparation and use
ZA976222B (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
AU2565595A (en) Amide derivatives having 5ht1d-antagonist activity
HK1003436A1 (en) Novel benzimidazole derivatives having cgmp-phosphodisterase inhibiting activity
GR3036757T3 (en) Optically active benzothiepin derivative, its preparation and use
AU703235B2 (en) 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives having PDE IV and cytokine inhibiting activity
HU9600272D0 (en) 10-amino-aliphatic-dibenzo-[b,f]oxepines of antineurodegenerative activity
AU9197598A (en) Inducing neurotransmitter and neuropeptide activity
HUP9900374A3 (en) Diarylalkenylamine derivatives and pharmaceutical compns. contg. them
PL327686A1 (en) Derivatives of @-amino 5,6-dichlorobenzimidazole exhibiting antiviral activity
ATE305455T1 (de) 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität
EP0866709A4 (en) 1,2,4-BENZOTHRIAZINE OXIDE FORMULATIONS
HUP0001792A3 (en) Dibenzo-oxazepine and-dioxepine derivatives and their use as anti-tumor agents
HUP9903260A3 (en) 2,4-diaminopyrimidine derivatives with antibiotic activity, preparation and use thereof
GB9425776D0 (en) 1,3,5-triazine derivatives,their preparations and uses
ZA965718B (en) New pyrido-thiopyranoindazoles with anti-tumor activity
SI0750614T1 (en) Quinazolinyl-amino derivatives having alpha-antagonist activity
GB2451221B (en) Azidoalkylformals, their prepararion and use
GB9602907D0 (en) Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA931546B (en) Acetamide derivative and application thereof.